Suppr超能文献

反复摄入超治疗剂量对乙酰氨基酚的临床病程。

Clinical course of repeated supratherapeutic ingestion of acetaminophen.

机构信息

Department of Emergency Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia.

出版信息

Clin Toxicol (Phila). 2011 Feb;49(2):108-12. doi: 10.3109/15563650.2011.554839.

Abstract

BACKGROUND

Repeated supratherapeutic ingestion (RSTI) of acetaminophen (APAP) is recognized as an important cause of APAP-related morbidity and mortality. This study describes the characteristics and clinical course of patients with RSTI, and identifies the risk factors for developing hepatotoxicity and death.

METHODS

This secondary analysis of a multicenter retrospective chart review studied patients treated with IV and/or oral N-acetylcysteine for acetaminophen poisoning. For this analysis, we included all subjects coded as RSTIs, defined as ingestions of greater than 4 g of APAP per 24 h over a period longer than 8 h. Data collected include demographics, coingestants, comorbidities, presenting laboratory data, and outcomes. The analysis includes descriptive statistics and associations of demographic and clinical factors with patient outcome.

RESULTS

Of the 503 patients enrolled, 119 (23.7%) were RSTI. The mean age was 39.6 years (SD ± 15); 63.9% of the patients were females, 60.5% Caucasians, 27.7% alcoholics, 5% malnourished, 10.9% had viral hepatitis, and 3.4% had other liver diseases. Coingestants included ethanol, opioids, and antihistamines (17.6, 48.7, and 19.3%, respectively). Among this group, 44 patients developed hepatotoxicity, two received liver transplants, and four died (37.0, 1.7, and 3.4%, respectively). The risk for hepatotoxicity increased with a history of alcoholism, viral hepatitis, and other liver diseases. A history of alcoholism and an elevated presenting serum creatinine were associated with increased risk for death/transplant. The lowest presenting ALT levels in a subject who developed hepatotoxicity and who died were 252 and 426 IU/l, respectively.

CONCLUSION

RSTI-induced hepatotoxicity and poor outcomes can be predicted at the patient's presentation. All patients with RSTI who developed hepatotoxicity presented with an abnormal ALT. A history of alcoholism and an elevated creatinine at presentation are markers of increased risk for hepatotoxicity and death.

摘要

背景

反复摄入(RSTI)超治疗剂量的对乙酰氨基酚(APAP)被认为是导致 APAP 相关发病率和死亡率的一个重要原因。本研究描述了 RSTI 患者的特征和临床病程,并确定了发生肝毒性和死亡的危险因素。

方法

这是一项多中心回顾性图表审查的二次分析,研究了接受 IV 和/或口服 N-乙酰半胱氨酸治疗的对乙酰氨基酚中毒患者。在这项分析中,我们纳入了所有编码为 RSTI 的患者,定义为在 8 小时以上的时间内,每 24 小时摄入超过 4 克的 APAP。收集的数据包括人口统计学资料、共服药物、合并症、就诊时的实验室数据和结果。分析包括描述性统计和人口统计学及临床因素与患者结局的关联。

结果

在纳入的 503 名患者中,有 119 名(23.7%)为 RSTI。患者的平均年龄为 39.6 岁(标准差 ± 15);63.9%为女性,60.5%为白种人,27.7%为酗酒者,5%为营养不良者,10.9%患有病毒性肝炎,3.4%患有其他肝病。共服药物包括乙醇、阿片类药物和抗组胺药(分别为 17.6%、48.7%和 19.3%)。在这一组中,有 44 名患者发生了肝毒性,2 名患者接受了肝移植,4 名患者死亡(分别为 37.0%、1.7%和 3.4%)。有酗酒史、病毒性肝炎和其他肝病的患者发生肝毒性的风险增加。有酗酒史和就诊时血清肌酐升高与死亡/移植风险增加相关。发生肝毒性和死亡的患者的 ALT 水平最低值分别为 252 和 426 IU/L。

结论

在患者就诊时可以预测 RSTI 引起的肝毒性和不良结局。所有发生肝毒性的 RSTI 患者就诊时的 ALT 均异常。酗酒史和就诊时肌酐升高是肝毒性和死亡风险增加的标志物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验